{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:52:52Z","timestamp":1790009572726,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemical synthesis of conjugate vaccines, consisting of a polysaccharide linked to a protein, can be technically challenging, and in vivo bacterial conjugations (bioconjugations) have emerged as manufacturing alternatives. Bioconjugation relies upon an oligosaccharyltransferase to attach polysaccharides to proteins, but currently employed enzymes are not suitable for the generation of conjugate vaccines when the polysaccharides contain glucose at the reducing end, which is the case for ~75% of <jats:italic>Streptococcus pneumoniae<\/jats:italic> capsules. Here, we use an <jats:italic>O<\/jats:italic>-linking oligosaccharyltransferase to generate a polyvalent pneumococcal bioconjugate vaccine with polysaccharides containing glucose at their reducing end. In addition, we show that different vaccine carrier proteins can be glycosylated using this system. Pneumococcal bioconjugates are immunogenic, protective and rapidly produced within <jats:italic>E. coli<\/jats:italic> using recombinant techniques. These proof-of-principle experiments establish a platform to overcome limitations of other conjugating enzymes enabling the development of bioconjugate vaccines for many important human and animal pathogens.<\/jats:p>","DOI":"10.1038\/s41467-019-08869-9","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T11:04:12Z","timestamp":1550747052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host"],"prefix":"10.1038","volume":"10","author":[{"given":"Christian M.","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichollas E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7158-9594","authenticated-orcid":false,"given":"Guillaume","family":"Goyette-Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Nothaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sthefany M.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Stallings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariela","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"8869_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1586\/14760584.2015.965160","volume":"14","author":"WP Hausdorff","year":"2015","unstructured":"Hausdorff, W. P., Hoet, B. & Adegbola, R. A. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert. Rev. Vaccin. 14, 413\u2013428 (2015).","journal-title":"Expert. Rev. Vaccin."},{"key":"8869_CR2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","volume":"374","author":"KL O\u2019Brien","year":"2009","unstructured":"O\u2019Brien, K. L. et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893\u2013902 (2009).","journal-title":"Lancet"},{"key":"8869_CR3","unstructured":"WHO. Estimated Hib and Pneumococcal Deaths for Children under 5 years of Age, 2008. http:\/\/www.who.int\/immunization\/monitoring_surveillance\/burden\/estimates\/Pneumo_hib\/en (2013)."},{"key":"8869_CR4","unstructured":"CDC. Pneumococcal Disease. https:\/\/www.cdc.gov\/pneumococcal\/vaccination.html (2017)."},{"key":"8869_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0264-410X(98)00097-8","volume":"16","author":"M Cadoz","year":"1998","unstructured":"Cadoz, M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 16, 1391\u20131395 (1998).","journal-title":"Vaccine"},{"key":"8869_CR6","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/nm.2535","volume":"17","author":"FY Avci","year":"2011","unstructured":"Avci, F. Y., Li, X., Tsuji, M. & Kasper, D. L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602\u20131609 (2011).","journal-title":"Nat. Med."},{"key":"8869_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","volume":"9","author":"AJ Pollard","year":"2009","unstructured":"Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein\u2013polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213\u2013220 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"8869_CR8","unstructured":"CDC. Vaccines for Children Program (VFC). https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html (2018)."},{"key":"8869_CR9","unstructured":"Pfizer. Pfizer Inc. 2017 Financial Report. https:\/\/www.sec.gov\/Archives\/edgar\/data\/78003\/000007800318000027\/pfe-exhibit13x12312017x10k.htm (2017)."},{"key":"8869_CR10","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","volume":"6","author":"B Wahl","year":"2018","unstructured":"Wahl, B. et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315. Lancet Glob. Health 6, e744\u2013e757 (2018).","journal-title":"Lancet Glob. Health"},{"issue":"Suppl. 2","key":"8869_CR11","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1097\/INF.0000000000000082","volume":"33","author":"JD Loo","year":"2014","unstructured":"Loo, J. D. et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr. Infect. Dis. J. 33, S140\u2013S151 (2014).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"8869_CR12","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.vaccine.2014.02.096","volume":"32","author":"JD Grabenstein","year":"2014","unstructured":"Grabenstein, J. D. & Musey, L. K. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 32, 2399\u20132405 (2014).","journal-title":"Vaccine"},{"key":"8869_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2016.1277300","volume":"13","author":"YA Cui","year":"2017","unstructured":"Cui, Y. A., Patel, H., O\u2019Neil, W. M., Li, S. & Saddier, P. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum. Vaccin. Immunother. 13, 1\u201313 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"8869_CR14","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.vaccine.2015.03.012","volume":"33","author":"RA Gladstone","year":"2015","unstructured":"Gladstone, R. A. et al. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine 33, 2015\u20132021 (2015).","journal-title":"Vaccine"},{"key":"8869_CR15","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1016\/j.vaccine.2009.06.013","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch, C. E. Preparation of bacterial polysaccharide\u2013protein conjugates: analytical and manufacturing challenges. Vaccine 27, 6468\u20136470 (2009).","journal-title":"Vaccine"},{"key":"8869_CR16","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1073\/pnas.0500044102","volume":"102","author":"MF Feldman","year":"2005","unstructured":"Feldman, M. F. et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc. Natl. Acad. Sci. USA 102, 3016\u20133021 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8869_CR17","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1473-3099(17)30108-1","volume":"17","author":"A Huttner","year":"2017","unstructured":"Huttner, A. et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect. Dis. 17, 528\u2013537 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"8869_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1128\/CVI.00224-16","volume":"23","author":"MS Riddle","year":"2016","unstructured":"Riddle, M. S. et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study. Clin. Vaccin. Immunol. 23, 908\u2013917 (2016).","journal-title":"Clin. Vaccin. Immunol."},{"key":"8869_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrmicro2383","volume":"8","author":"H Nothaft","year":"2010","unstructured":"Nothaft, H. & Szymanski, C. M. Protein glycosylation in bacteria: sweeter than ever. Nat. Rev. Microbiol. 8, 765\u2013778 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"8869_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/mmi.12265","volume":"89","author":"JA Iwashkiw","year":"2013","unstructured":"Iwashkiw, J. A., Vozza, N. F., Kinsella, R. L. & Feldman, M. F. Pour some sugar on it: the expanding world of bacterial protein O-linked glycosylation. Mol. Microbiol. 89, 14\u201328 (2013).","journal-title":"Mol. Microbiol."},{"key":"8869_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/CMR.00024-15","volume":"28","author":"KA Geno","year":"2015","unstructured":"Geno, K. A. et al. Pneumococcal capsules and their types: past, present, and future. Clin. Microbiol. Rev. 28, 871\u2013899 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"8869_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1475-2859-11-13","volume":"11","author":"JA Iwashkiw","year":"2012","unstructured":"Iwashkiw, J. A. et al. Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis. Microb. Cell Fact. 11, 13 (2012).","journal-title":"Microb. Cell Fact."},{"key":"8869_CR23","doi-asserted-by":"publisher","first-page":"e2048","DOI":"10.1371\/journal.pntd.0002048","volume":"7","author":"AE Ciocchini","year":"2013","unstructured":"Ciocchini, A. E. et al. Development and validation of a novel diagnostic test for human brucellosis using a glyco-engineered antigen coupled to magnetic beads. PLoS Negl. Trop. Dis. 7, e2048 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"8869_CR24","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.1073\/pnas.0509207103","volume":"103","author":"M Wacker","year":"2006","unstructured":"Wacker, M. et al. Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems. Proc. Natl. Acad. Sci. USA 103, 7088\u20137093 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8869_CR25","doi-asserted-by":"publisher","first-page":"34596","DOI":"10.1074\/jbc.M807113200","volume":"283","author":"A Faridmoayer","year":"2008","unstructured":"Faridmoayer, A. et al. Extreme substrate promiscuity of the Neisseria oligosaccharyl transferase involved in protein O-glycosylation. J. Biol. Chem. 283, 34596\u201334604 (2008).","journal-title":"J. Biol. Chem."},{"key":"8869_CR26","doi-asserted-by":"publisher","first-page":"8088","DOI":"10.1128\/JB.01318-07","volume":"189","author":"A Faridmoayer","year":"2007","unstructured":"Faridmoayer, A., Fentabil, M. A., Mills, D. C., Klassen, J. S. & Feldman, M. F. Functional characterization of bacterial oligosaccharyltransferases involved in O-linked protein glycosylation. J. Bacteriol. 189, 8088\u20138098 (2007).","journal-title":"J. Bacteriol."},{"key":"8869_CR27","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1371\/journal.pgen.0020031","volume":"2","author":"SD Bentley","year":"2006","unstructured":"Bentley, S. D. et al. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2, e31 (2006).","journal-title":"PLoS Genet."},{"key":"8869_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/mmi.12986","volume":"96","author":"CM Harding","year":"2015","unstructured":"Harding, C. M. et al. Acinetobacter strains carry two functional oligosaccharyltransferases, one devoted exclusively to type IV pilin, and the other one dedicated to O-glycosylation of multiple proteins. Mol. Microbiol. 96, 1023\u20131041 (2015).","journal-title":"Mol. Microbiol."},{"key":"8869_CR29","doi-asserted-by":"publisher","first-page":"140227","DOI":"10.1098\/rsob.140227","volume":"5","author":"J Ihssen","year":"2015","unstructured":"Ihssen, J. et al. Increased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering. Open Biol. 5, 140227 (2015).","journal-title":"Open Biol."},{"key":"8869_CR30","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/sj.emboj.7601087","volume":"25","author":"M Kowarik","year":"2006","unstructured":"Kowarik, M. et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J. 25, 1957\u20131966 (2006).","journal-title":"EMBO J."},{"key":"8869_CR31","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1073\/pnas.0809504106","volume":"106","author":"A Vik","year":"2009","unstructured":"Vik, A. et al. Broad spectrum O-linked protein glycosylation in the human pathogen Neisseria gonorrhoeae. Proc. Natl. Acad. Sci. USA 106, 4447\u20134452 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"8869_CR32","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1074\/mcp.M114.038315","volume":"13","author":"NE Scott","year":"2014","unstructured":"Scott, N. E. et al. Diversity within the O-linked protein glycosylation systems of Acinetobacter species. Mol. Cell. Proteom. 13, 2354\u20132370 (2014).","journal-title":"Mol. Cell. Proteom."},{"key":"8869_CR33","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1128\/IAI.70.6.2837-2845.2002","volume":"70","author":"JE Comer","year":"2002","unstructured":"Comer, J. E., Marshall, M. A., Blanch, V. J., Deal, C. D. & Castric, P. Identification of the Pseudomonas aeruginosa 1244 pilin glycosylation site. Infect. Immun. 70, 2837\u20132845 (2002).","journal-title":"Infect. Immun."},{"key":"8869_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1086\/323648","volume":"184","author":"T Wuorimaa","year":"2001","unstructured":"Wuorimaa, T. et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184, 1211\u20131215 (2001).","journal-title":"J. Infect. Dis."},{"key":"8869_CR35","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/S0264-410X(98)00475-7","volume":"17","author":"A Soininen","year":"1999","unstructured":"Soininen, A., Seppala, I., Nieminen, T., Eskola, J. & Kayhty, H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17, 1889\u20131897 (1999).","journal-title":"Vaccine"},{"key":"8869_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1086\/648593","volume":"201","author":"T Pilishvili","year":"2010","unstructured":"Pilishvili, T. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201, 32\u201341 (2010).","journal-title":"J. Infect. Dis."},{"key":"8869_CR37","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1016\/j.vaccine.2018.05.036","volume":"36","author":"JA Herbert","year":"2018","unstructured":"Herbert, J. A. et al. Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine. Vaccine 36, 3809\u20133819 (2018).","journal-title":"Vaccine"},{"key":"8869_CR38","doi-asserted-by":"publisher","first-page":"e00443","DOI":"10.1128\/mBio.00443-16","volume":"7","author":"C Pan","year":"2016","unstructured":"Pan, C. et al. Biosynthesis of conjugate vaccines using an O-linked glycosylation system. mBio 7, e00443\u201300416 (2016).","journal-title":"mBio"},{"key":"8869_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0037-1","volume":"3","author":"P Sun","year":"2018","unstructured":"Sun, P. et al. Design and production of conjugate vaccines against S. paratyphi A using an O-linked glycosylation system in vivo. NPJ Vaccin. 3, 4 (2018).","journal-title":"NPJ Vaccin."},{"issue":"Part 5","key":"8869_CR40","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1099\/13500872-141-5-1247","volume":"141","author":"P Castric","year":"1995","unstructured":"Castric, P. pilO, a gene required for glycosylation of Pseudomonas aeruginosa 1244 pilin. Microbiology 141, 1247\u20131254 (1995).","journal-title":"Microbiology"},{"key":"8869_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2958.2007.05806.x","volume":"65","author":"FE Aas","year":"2007","unstructured":"Aas, F. E., Vik, A., Vedde, J., Koomey, M. & Egge-Jacobsen, W. Neisseria gonorrhoeae O-linked pilin glycosylation: functional analyses define both the biosynthetic pathway and glycan structure. Mol. Microbiol. 65, 607\u2013624 (2007).","journal-title":"Mol. Microbiol."},{"key":"8869_CR42","doi-asserted-by":"publisher","first-page":"27712","DOI":"10.1074\/jbc.M604324200","volume":"281","author":"FE Aas","year":"2006","unstructured":"Aas, F. E. et al. Neisseria gonorrhoeae type IV pili undergo multisite, hierarchical modifications with phosphoethanolamine and phosphocholine requiring an enzyme structurally related to lipopolysaccharide phosphoethanolamine transferases. J. Biol. Chem. 281, 27712\u201327723 (2006).","journal-title":"J. Biol. Chem."},{"key":"8869_CR43","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"8869_CR44","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1021\/pr050385q","volume":"5","author":"Y Ishihama","year":"2006","unstructured":"Ishihama, Y., Rappsilber, J. & Mann, M. Modular stop and go extraction tips with stacked disks for parallel and multidimensional peptide fractionation in proteomics. J. Proteome Res. 5, 988\u2013994 (2006).","journal-title":"J. Proteome Res."},{"key":"8869_CR45","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/nprot.2007.261","volume":"2","author":"J Rappsilber","year":"2007","unstructured":"Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896\u20131906 (2007).","journal-title":"Nat. Protoc."},{"key":"8869_CR46","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/bms.1200111109","volume":"11","author":"P Roepstorff","year":"1984","unstructured":"Roepstorff, P. & Fohlman, J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed. Mass Spectrom. 11, 601 (1984).","journal-title":"Biomed. Mass Spectrom."},{"key":"8869_CR47","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-4939-2874-3_6","volume":"1331","author":"G Goyette-Desjardins","year":"2015","unstructured":"Goyette-Desjardins, G., Roy, R. & Segura, M. Murine whole-blood opsonophagocytosis assay to evaluate protection by antibodies raised against encapsulated extracellular bacteria. Methods Mol. Biol. 1331, 81\u201392 (2015).","journal-title":"Methods Mol. Biol."},{"key":"8869_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/srep24931","volume":"6","author":"NL Price","year":"2016","unstructured":"Price, N. L. et al. Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci. Rep. 6, 24931 (2016).","journal-title":"Sci. Rep."},{"key":"8869_CR49","doi-asserted-by":"publisher","first-page":"150243","DOI":"10.1098\/rsob.150243","volume":"6","author":"EJ Kay","year":"2016","unstructured":"Kay, E. J., Yates, L. E., Terra, V. S., Cuccui, J. & Wren, B. W. Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli. Open Biol. 6, 150243 (2016).","journal-title":"Open Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08869-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08869-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08869-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:15:16Z","timestamp":1671225316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-08869-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["8869"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-08869-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"7 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"891"}}